https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-ovarian-cancer-trial-results BiopharmaWatch en 2026-10-23T15:55:00.000Z Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer https://www.biopharmawatch.com/news/NVS/novartis-remibrutinib-phase-iii-results-ms BiopharmaWatch en 2026-10-23T15:45:00.000Z Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-phase-1-azer-cel-progressive-ms BiopharmaWatch en 2026-10-23T14:55:00.000Z TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 https://www.biopharmawatch.com/news/CATX/perspectives-212pb-bamzireotide-navoxetan-phase-1-2a-trial BiopharmaWatch en 2026-10-23T14:49:00.000Z Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-phase-1-breakfree-2-study-results BiopharmaWatch en 2026-10-23T14:30:00.000Z Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-miv-cel-ms-toronto-2026 BiopharmaWatch en 2026-10-23T14:30:00.000Z Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 https://www.biopharmawatch.com/news/JAZZ/ziihera-combinations-survival-her2-advanced-gea BiopharmaWatch en 2026-10-23T14:15:00.000Z Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 https://www.biopharmawatch.com/news/ONC/beone-medicines-tevimabra-ziihira-gastroesophageal-cancer BiopharmaWatch en 2026-10-23T14:15:00.000Z BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-denali-study-esmo-2026 BiopharmaWatch en 2026-10-23T14:15:00.000Z Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 https://www.biopharmawatch.com/news/IOVA/iovance-lifileucel-pembrolizumab-esmo-2026 BiopharmaWatch en 2026-10-23T14:15:00.000Z Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma https://www.biopharmawatch.com/news/XBIT/xbiotech-announces-co-ceo-appointments BiopharmaWatch en 2026-10-23T13:17:00.000Z XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers https://www.biopharmawatch.com/news/FTH/faeth-updated-preclinical-data-esmo-2026 BiopharmaWatch en 2026-10-23T13:15:00.000Z Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib https://www.biopharmawatch.com/news/ABT/abbott-esmo-data-oncodetect-test-colorectal-cancer BiopharmaWatch en 2026-10-23T13:15:00.000Z Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer https://www.biopharmawatch.com/news/CELC/celcuity-phase-1b-2-gedatolisib-darolutamide-esmo-2026 BiopharmaWatch en 2026-10-23T13:15:00.000Z Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-esmo-congress-data BiopharmaWatch en 2026-10-23T13:15:00.000Z Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/KTTA/pasithea-positive-pas-004-clinical-data-esmo-2026 BiopharmaWatch en 2026-10-23T13:15:00.000Z Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 https://www.biopharmawatch.com/news/MGNX/macrogenics-positive-phase-1-results-mgc026 BiopharmaWatch en 2026-10-23T13:15:00.000Z MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-acquires-prana-therapies BiopharmaWatch en 2026-10-23T13:08:00.000Z Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ifetroban-dmd-webcast BiopharmaWatch en 2026-10-23T13:05:00.000Z CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL https://www.biopharmawatch.com/news/BMY/pathos-ai-bms-tempus-ai-collaboration-alzheimers BiopharmaWatch en 2026-10-23T13:00:00.000Z Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions https://www.biopharmawatch.com/news/BMY/tempus-expands-collaboration-bristol-myers-squibb BiopharmaWatch en 2026-10-23T13:00:00.000Z Tempus Expands Strategic Collaboration with Bristol Myers Squibb https://www.biopharmawatch.com/news/LIVN/livanova-core-vns-results-drug-resistant-epilepsy BiopharmaWatch en 2026-10-23T13:00:00.000Z Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy https://www.biopharmawatch.com/news/BMY/pathos-ai-secures-237-million-series-e-financing BiopharmaWatch en 2026-10-23T13:00:00.000Z Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-fall-collectibles-nostalgic-favorites BiopharmaWatch en 2026-10-23T13:00:00.000Z CVS Pharmacy expands fall assortment of collectibles, nostalgic favorites and seasonal exclusives https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-amplify-7p-results-esmo-2026 BiopharmaWatch en 2026-10-23T13:00:00.000Z Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-sonata-hcm-update BiopharmaWatch en 2026-10-23T12:30:00.000Z Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy https://www.biopharmawatch.com/news/IRMD/iradimed-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-23T12:30:00.000Z IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026 https://www.biopharmawatch.com/news/ONCO/onconetix-additional-financing-realbotix-acquisition BiopharmaWatch en 2026-10-23T12:30:00.000Z Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition https://www.biopharmawatch.com/news/MBOT/microbot-medical-sir-edge-2026-conference BiopharmaWatch en 2026-10-23T12:30:00.000Z Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S. https://www.biopharmawatch.com/news/WAT/waters-labcorp-hpv-testing-expansion-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026 https://www.biopharmawatch.com/news/LH/labcorp-waters-hpv-testing-expansion-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026 https://www.biopharmawatch.com/news/LH/labcorp-acquires-millennium-health BiopharmaWatch en 2026-10-23T12:00:00.000Z Labcorp Announces Definitive Agreement to Acquire Millennium Health https://www.biopharmawatch.com/news/IMMP/immutep-quality-of-life-data-esmo-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 https://www.biopharmawatch.com/news/HUMA/humacyte-atev-phase-3-trial-results BiopharmaWatch en 2026-10-23T12:00:00.000Z Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-invincible-4-study-esmo-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting https://www.biopharmawatch.com/news/ATNM/actinium-phase-1-study-atnm-400-esmo-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 https://www.biopharmawatch.com/news/NVS/kisqali-natalee-trial-results-breast-cancer BiopharmaWatch en 2026-10-23T11:30:00.000Z Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence https://www.biopharmawatch.com/news/BMY/iza-bren-reduces-risk-in-advanced-breast-cancer BiopharmaWatch en 2026-10-23T11:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study https://www.biopharmawatch.com/news/BMY/iza-bren-phase-3-results-breast-cancer BiopharmaWatch en 2026-10-23T11:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study https://www.biopharmawatch.com/news/TAK/takeda-tak-921-phase-3-advanced-gastric-cancer-study BiopharmaWatch en 2026-10-23T11:30:00.000Z Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study https://www.biopharmawatch.com/news/BCTX/briacell-esmo-2026-circulating-immune-biomarker BiopharmaWatch en 2026-10-23T11:30:00.000Z BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer https://www.biopharmawatch.com/news/RVMD/rasonque-overall-survival-data-esmo-2026 BiopharmaWatch en 2026-10-23T11:30:00.000Z Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026 https://www.biopharmawatch.com/news/JNJ/ec-approves-johnson-johnson-tecvayli-multiple-myeloma BiopharmaWatch en 2026-10-23T11:09:00.000Z European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse https://www.biopharmawatch.com/news/TMCI/treace-report-third-quarter-2026-results BiopharmaWatch en 2026-10-23T11:05:00.000Z Treace to Report Third Quarter 2026 Financial Results on November 6, 2026 https://www.biopharmawatch.com/news/MRNA/moderna-top-employer-science-2026 BiopharmaWatch en 2026-10-23T11:00:00.000Z Moderna Named a Top Employer by Science for Twelfth Consecutive Year https://www.biopharmawatch.com/news/BLRX/biolinerx-hemispherian-present-preclinical-data-demonstrating-synergy-glix1-parp BiopharmaWatch en 2026-10-23T11:00:00.000Z BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 https://www.biopharmawatch.com/news/BKD/brookdale-q3-2026-earnings-release-conference-call BiopharmaWatch en 2026-10-23T11:00:00.000Z Brookdale Announces Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-hero-trial-data BiopharmaWatch en 2026-10-23T11:00:00.000Z Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q3-2026-financial-results-discussion BiopharmaWatch en 2026-10-23T10:55:00.000Z ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET https://www.biopharmawatch.com/news/MEDS/datameds-ai-health-lives-here-community-respiratory-program BiopharmaWatch en 2026-10-23T10:45:00.000Z DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network https://www.biopharmawatch.com/news/ZLAB/zai-lab-zocilurtatug-pelitecan-es-sclc-trial-results BiopharmaWatch en 2026-10-23T10:33:00.000Z Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer https://www.biopharmawatch.com/news/TNGX/tango-phase-1-2-study-vopimetostat-daraxonrasib BiopharmaWatch en 2026-10-23T10:30:00.000Z Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy https://www.biopharmawatch.com/news/IDYA/ide849-updated-phase-1-results-esmo-2026 BiopharmaWatch en 2026-10-23T10:00:00.000Z IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas https://www.biopharmawatch.com/news/ZYME/zymeworks-roche-license-agreement-zw209 BiopharmaWatch en 2026-10-23T10:00:00.000Z Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 https://www.biopharmawatch.com/news/PHAT/phathom-update-litigation-bdr-fda BiopharmaWatch en 2026-10-23T08:00:00.000Z Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA https://www.biopharmawatch.com/news/ALNY/alny-positive-phase-1b-data-brezosiran-huntingtons-disease BiopharmaWatch en 2026-10-23T07:45:00.000Z Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-rinzimetostat-esmo-congress-2026 BiopharmaWatch en 2026-10-23T07:15:00.000Z ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-enozertinib-phase-3-trial BiopharmaWatch en 2026-10-23T07:15:00.000Z ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial https://www.biopharmawatch.com/news/EVAX/evaxion-evx-01-three-year-trial-results BiopharmaWatch en 2026-10-23T06:00:00.000Z Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-private-placement-250-million BiopharmaWatch en 2026-10-23T00:52:00.000Z Zai Lab Announces $250 Million Private Placement https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-voluntarily-delist-nasdaq BiopharmaWatch en 2026-10-22T23:00:00.000Z Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-asn-kidney-week-2026 BiopharmaWatch en 2026-10-22T22:40:00.000Z Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-emerging-growth-conference BiopharmaWatch en 2026-10-22T22:27:00.000Z Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference https://www.biopharmawatch.com/news/ENLV/enlivex-reverse-share-split-effective-october-2026 BiopharmaWatch en 2026-10-22T21:16:00.000Z Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026 https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-leadership-update BiopharmaWatch en 2026-10-22T21:00:00.000Z MindWalk Holdings Corp. Announces Leadership Update https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-third-quarter-2026-results BiopharmaWatch en 2026-10-22T20:43:00.000Z Nu Skin Enterprises to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/FOCL/focaltherics-third-quarter-2026-results-announcement BiopharmaWatch en 2026-10-22T20:30:27.000Z FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/LH/charles-river-labcorp-fda-collaboration-abuse-potential BiopharmaWatch en 2026-10-22T20:30:00.000Z Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment https://www.biopharmawatch.com/news/AGEN/agenus-third-quarter-2026-financial-report BiopharmaWatch en 2026-10-22T20:30:00.000Z Agenus to Provide Third Quarter 2026 Financial Report and Development Update https://www.biopharmawatch.com/news/LH/labcorp-fda-charles-river-research-collaboration-drug-abuse-potential BiopharmaWatch en 2026-10-22T20:30:00.000Z Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential https://www.biopharmawatch.com/news/EHC/encompass-health-westover-hills-open-texas BiopharmaWatch en 2026-10-22T20:30:00.000Z Encompass Health Rehabilitation Hospital of Westover Hills now open in Texas https://www.biopharmawatch.com/news/CVRX/cvrx-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-10-22T20:30:00.000Z CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-medicare-reimbursement-esoguard-financing BiopharmaWatch en 2026-10-22T20:20:00.000Z Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing https://www.biopharmawatch.com/news/PROF/montel-williams-joins-lets-huddle-webinar BiopharmaWatch en 2026-10-22T20:15:00.000Z Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar https://www.biopharmawatch.com/news/CDRE/cadre-holdings-q3-2026-earnings-call BiopharmaWatch en 2026-10-22T20:15:00.000Z Cadre Holdings Announces Third Quarter 2026 Earnings and Conference Call Information https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-conference-call-q3-2026 BiopharmaWatch en 2026-10-22T20:11:00.000Z Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AORT/artivion-q3-2026-financial-results-teleconference BiopharmaWatch en 2026-10-22T20:10:00.000Z Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/VOR/telitacicept-preserves-kidney-function-phase-3-trial BiopharmaWatch en 2026-10-22T20:05:17.000Z Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy https://www.biopharmawatch.com/news/ABCL/abcellera-investor-conferences-november-2026 BiopharmaWatch en 2026-10-22T20:05:00.000Z AbCellera to Present at Upcoming Investor Conferences in November 2026 https://www.biopharmawatch.com/news/ABCL/abcellera-present-investor-conferences-november-2026 BiopharmaWatch en 2026-10-22T20:05:00.000Z AbCellera to Present at Upcoming Investor Conferences in November 2026 https://www.biopharmawatch.com/news/ACH/accendra-health-q3-2026-earnings-release BiopharmaWatch en 2026-10-22T20:05:00.000Z Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/PIII/p3-health-partners-q3-2026-earnings-release BiopharmaWatch en 2026-10-22T20:05:00.000Z P3 Health Partners Schedules Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-q3-2026-results-conference-call BiopharmaWatch en 2026-10-22T20:05:00.000Z Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026 https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261022 BiopharmaWatch en 2026-10-22T20:05:00.000Z Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GILD/gilead-acquires-hcxt-2001-inflammation-pipeline BiopharmaWatch en 2026-10-22T20:05:00.000Z Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD https://www.biopharmawatch.com/news/HCAT/health-catalyst-q3-2026-results-conference-call BiopharmaWatch en 2026-10-22T20:05:00.000Z Health Catalyst to Announce Third Quarter 2026 Operating Results and Host Conference Call on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-fda-lifts-hold-ard-101 BiopharmaWatch en 2026-10-22T20:05:00.000Z Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data https://www.biopharmawatch.com/news/FTRE/fortrea-omico-collaboration-precision-oncology BiopharmaWatch en 2026-10-22T20:05:00.000Z Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development https://www.biopharmawatch.com/news/TMDX/transmedics-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-22T20:05:00.000Z TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-hyperphagia-prader-willi-syndrome BiopharmaWatch en 2026-10-22T20:05:00.000Z Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261022 BiopharmaWatch en 2026-10-22T20:05:00.000Z Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ELUT/elutia-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-22T20:05:00.000Z Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q3-2026-results-call BiopharmaWatch en 2026-10-22T20:01:00.000Z Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026 https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q3-2026-results-business-update BiopharmaWatch en 2026-10-22T20:01:00.000Z Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026 https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-22T20:01:00.000Z Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/ANIK/anika-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-22T20:01:00.000Z Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/LGND/ligand-investor-day-december-2026 BiopharmaWatch en 2026-10-22T20:01:00.000Z Ligand to Host Investor Day on December 8, 2026 https://www.biopharmawatch.com/news/ACET/adicet-bio-investor-conferences-november-2026 BiopharmaWatch en 2026-10-22T20:00:00.000Z Adicet Bio to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/COSM/cosmos-health-expands-ecommerce-oceania BiopharmaWatch en 2026-10-22T19:55:00.000Z Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway https://www.biopharmawatch.com/news/MRK/merck-moderna-intismeran-trial-results-esmo-2026 BiopharmaWatch en 2026-10-22T18:59:00.000Z Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium https://www.biopharmawatch.com/news/IONS/ionis-ranked-top-employer-science-survey BiopharmaWatch en 2026-10-22T18:25:00.000Z Ionis ranked #1 on Science’s Top Employers list https://www.biopharmawatch.com/news/ICU/seastar-medical-quellimmune-pediatric-sepsis-aki BiopharmaWatch en 2026-10-22T16:01:00.000Z SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI https://www.biopharmawatch.com/news/IFRX/izicopan-therapeutic-potential-kidney-week-2026 BiopharmaWatch en 2026-10-22T16:00:00.000Z InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026 https://www.biopharmawatch.com/news/LLY/lilly-expands-manufacturing-richmond-virginia BiopharmaWatch en 2026-10-22T14:30:00.000Z Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020 https://www.biopharmawatch.com/news/VERA/vera-therapeutics-origins-3-results-trutakna BiopharmaWatch en 2026-10-22T14:05:00.000Z Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine https://www.biopharmawatch.com/news/VSEE/vsee-health-shareholder-letter-update BiopharmaWatch en 2026-10-22T13:30:00.000Z VSee Health Shareholder Letter https://www.biopharmawatch.com/news/NTHI/neonc-brain-cancer-milestones-spotlight BiopharmaWatch en 2026-10-22T13:28:00.000Z NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight https://www.biopharmawatch.com/news/MYGN/myriad-genetics-monstr-screen-3-data-mrd-detection BiopharmaWatch en 2026-10-22T13:05:00.000Z Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers https://www.biopharmawatch.com/news/SINT/sintx-technologies-q3-2026-earnings-release-webcast BiopharmaWatch en 2026-10-22T13:00:47.000Z SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast https://www.biopharmawatch.com/news/CON/concentra-expands-presence-pensacola-health-center BiopharmaWatch en 2026-10-22T13:00:00.000Z Concentra Expands Presence on Gulf Coast with First Pensacola Health Center https://www.biopharmawatch.com/news/AMGN/amgen-foundation-tops-75-million-hands-biotechnology-education-reaching-100 BiopharmaWatch en 2026-10-22T13:00:00.000Z AMGEN FOUNDATION TOPS $75 MILLION IN HANDS-ON BIOTECHNOLOGY EDUCATION, REACHING 100,000 STUDENTS A YEAR https://www.biopharmawatch.com/news/AMGN/amgen-foundation-biotechnology-education-commitment BiopharmaWatch en 2026-10-22T13:00:00.000Z AMGEN FOUNDATION TOPS $75 MILLION IN HANDS-ON BIOTECHNOLOGY EDUCATION, REACHING 100,000 STUDENTS A YEAR https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-q3-2026 BiopharmaWatch en 2026-10-22T13:00:00.000Z UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reverse-stock-split-nasdaq BiopharmaWatch en 2026-10-22T13:00:00.000Z Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing https://www.biopharmawatch.com/news/SBC/sbc-medical-dna-methylation-test-biological-age BiopharmaWatch en 2026-10-22T13:00:00.000Z SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-reverse-stock-split BiopharmaWatch en 2026-10-22T13:00:00.000Z Glucotrack, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/ABBV/abbvie-intrepid-trial-results-lutikizumab-hidradenitis-suppurativa BiopharmaWatch en 2026-10-22T13:00:00.000Z AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa https://www.biopharmawatch.com/news/BMY/ihi-bristol-myers-squibb-cancer-collaborative BiopharmaWatch en 2026-10-22T12:55:00.000Z IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-fda-phase-iib-trial-tourette-syndrome BiopharmaWatch en 2026-10-22T12:55:00.000Z SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-erna-101-clinic-path BiopharmaWatch en 2026-10-22T12:53:00.000Z Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment https://www.biopharmawatch.com/news/EHC/encompass-health-declares-dividend-common-stock-20261022 BiopharmaWatch en 2026-10-22T12:52:00.000Z Encompass Health declares dividend on common stock https://www.biopharmawatch.com/news/RNXT/renovorx-third-quarter-2026-results BiopharmaWatch en 2026-10-22T12:45:00.000Z RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 https://www.biopharmawatch.com/news/PROK/prokidney-hosts-virtual-kol-event-recap-asn-kidney-week BiopharmaWatch en 2026-10-22T12:45:00.000Z ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update https://www.biopharmawatch.com/news/NAGE/niagen-plus-liquid-at-home-injections-launch BiopharmaWatch en 2026-10-22T12:38:00.000Z Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion https://www.biopharmawatch.com/news/MSA/msas-altaio-6-contract-northeast-utility BiopharmaWatch en 2026-10-22T12:35:00.000Z MSA Safety Announces ALTAIR io™ 6 Contract with Major Northeast U.S. Utility Provider https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-22T12:30:00.000Z Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HALO/halozyme-q3-2026-results-conference-call BiopharmaWatch en 2026-10-22T12:30:00.000Z Halozyme to Report Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-rd-day-avim-therapy-virtue-sab BiopharmaWatch en 2026-10-22T12:30:00.000Z Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB https://www.biopharmawatch.com/news/PPCB/propanc-reverse-stock-split-nasdaq-growth-plans BiopharmaWatch en 2026-10-22T12:30:00.000Z Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-conferences-analyst-day BiopharmaWatch en 2026-10-22T12:30:00.000Z Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day https://www.biopharmawatch.com/news/ICUI/icu-medical-q3-2026-earnings-call BiopharmaWatch en 2026-10-22T12:30:00.000Z ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/VCEL/vericel-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-22T12:30:00.000Z Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/HYPR/hyperfine-swoop-system-model-2-rollout BiopharmaWatch en 2026-10-22T12:15:00.000Z Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-maria-ostrovsky-general-counsel BiopharmaWatch en 2026-10-22T12:05:00.000Z Candel Therapeutics Appoints Maria Ostrovsky as General Counsel https://www.biopharmawatch.com/news/SCNX/scienture-shareholder-letter-revenue-growth-fda-products BiopharmaWatch en 2026-10-22T12:05:00.000Z SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027 https://www.biopharmawatch.com/news/STXS/stxs-robotic-navigation-system-latvia BiopharmaWatch en 2026-10-22T12:04:00.000Z Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia https://www.biopharmawatch.com/news/NTHI/neonc-technologies-health-uncensored-dr-drew BiopharmaWatch en 2026-10-22T12:00:53.000Z NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy https://www.biopharmawatch.com/news/VMD/viemed-healthcare-q3-2026-earnings-call-details BiopharmaWatch en 2026-10-22T12:00:00.000Z Viemed Healthcare Announces Third Quarter 2026 Earnings Conference Call Details https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-webcast-conference-call-q3-2026 BiopharmaWatch en 2026-10-22T12:00:00.000Z Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates https://www.biopharmawatch.com/news/XERS/xeris-biopharma-q3-2026-results-release BiopharmaWatch en 2026-10-22T12:00:00.000Z Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 https://www.biopharmawatch.com/news/UNH/unitedhealthcare-support-northeast-missouri-health-council BiopharmaWatch en 2026-10-22T12:00:00.000Z UnitedHealthcare to Support Northeast Missouri Health Council Efforts to Sustain and Expand Rural Maternal Healthcare https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-q3-earnings-release-date BiopharmaWatch en 2026-10-22T12:00:00.000Z Sonida Senior Living Announces Third Quarter Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/AUNA/auna-preliminary-update-full-year-2026-outlook BiopharmaWatch en 2026-10-22T12:00:00.000Z Auna Announces Preliminary Update to Full-Year 2026 Outlook https://www.biopharmawatch.com/news/GILD/gilead-new-data-liver-diseases-liver-meeting-2026 BiopharmaWatch en 2026-10-22T12:00:00.000Z Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-announces-share-consolidation-20261022 BiopharmaWatch en 2026-10-22T12:00:00.000Z China SXT Pharmaceuticals, Inc. Announces Share Consolidation https://www.biopharmawatch.com/news/CYRX/cryoport-q3-2026-financial-results-report BiopharmaWatch en 2026-10-22T12:00:00.000Z Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/APYX/apyx-medical-q3-2026-financial-results-release BiopharmaWatch en 2026-10-22T12:00:00.000Z Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/ANVS/annovis-ctad-2026-presentations BiopharmaWatch en 2026-10-22T12:00:00.000Z Annovis to Attend the CTAD 2026 with Three Presentations https://www.biopharmawatch.com/news/CELU/celularity-regains-nasdaq-compliance-reporting-requirements BiopharmaWatch en 2026-10-22T12:00:00.000Z Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-achieves-milestones-growth-capital BiopharmaWatch en 2026-10-22T12:00:00.000Z Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility https://www.biopharmawatch.com/news/PROK/prokidney-announces-eight-abstracts-selected-presentation-american-society-nephrology-s BiopharmaWatch en 2026-10-22T12:00:00.000Z ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026 https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q3-2026-results-report BiopharmaWatch en 2026-10-22T12:00:00.000Z Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/MIRA/mira-55-significant-pain-relief-study BiopharmaWatch en 2026-10-22T12:00:00.000Z MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study https://www.biopharmawatch.com/news/REPL/replimune-fiscal-q2-2027-results-update BiopharmaWatch en 2026-10-22T12:00:00.000Z Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 https://www.biopharmawatch.com/news/COLL/collegium-report-third-quarter-2026-results BiopharmaWatch en 2026-10-22T12:00:00.000Z Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/SCYX/scynexis-phase-1-study-scy-247-results BiopharmaWatch en 2026-10-22T12:00:00.000Z SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-22T12:00:00.000Z LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/DMAC/diamedica-reports-200th-patient-enrollment-remedy2-trial BiopharmaWatch en 2026-10-22T12:00:00.000Z DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-crb-913-obesity-week-2026 BiopharmaWatch en 2026-10-22T12:00:00.000Z Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 https://www.biopharmawatch.com/news/JNJ/jnj-varipulse-omnipulse-af-data-aphrs-2026 BiopharmaWatch en 2026-10-22T11:45:00.000Z Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026 https://www.biopharmawatch.com/news/MEDS/datameds-ai-amended-loi-license-acquire-ip BiopharmaWatch en 2026-10-22T11:40:00.000Z DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q3-2026-financial-results BiopharmaWatch en 2026-10-22T11:30:00.000Z Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/HSDT/solana-company-selected-strategic-enterprise-hong-kong BiopharmaWatch en 2026-10-22T11:30:00.000Z Solana Company Selected as a Strategic Enterprise by the Hong Kong SAR Government https://www.biopharmawatch.com/news/ABUS/arbutus-fda-clinical-hold-lifted-ab-101 BiopharmaWatch en 2026-10-22T11:30:00.000Z Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-altitude-ad-trial-ctad-conference BiopharmaWatch en 2026-10-22T11:30:00.000Z Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference https://www.biopharmawatch.com/news/BBIO/bridgebio-q3-2026-financial-results-update BiopharmaWatch en 2026-10-22T11:30:00.000Z BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET https://www.biopharmawatch.com/news/CDNA/caredx-new-koar-data-asn-kidney-week-2026 BiopharmaWatch en 2026-10-22T11:05:00.000Z CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/TLRY/blue-point-brewing-cask-ales-festival-2026 BiopharmaWatch en 2026-10-22T11:00:48.000Z Blue Point Brewing Co.’s Legendary Cask Ales Festival Returns to Patchogue with 100+ Limited-Release Brews https://www.biopharmawatch.com/news/CGC/canopy-growth-q2-fiscal-2027-results-november-2026 BiopharmaWatch en 2026-10-22T11:00:00.000Z Canopy Growth to Report Second Quarter Fiscal 2027 Financial Results on November 6, 2026 https://www.biopharmawatch.com/news/UTHR/united-therapeutics-share-repurchase-authorization BiopharmaWatch en 2026-10-22T11:00:00.000Z United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization https://www.biopharmawatch.com/news/MDT/medtronic-positive-results-sphere-9-pulse-select-aphrs-2026 BiopharmaWatch en 2026-10-22T11:00:00.000Z Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026 https://www.biopharmawatch.com/news/KRRO/korro-preclinical-data-krro-111-aatd BiopharmaWatch en 2026-10-22T11:00:00.000Z Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency https://www.biopharmawatch.com/news/GUTS/fractyl-health-revital-focus-fda-submission BiopharmaWatch en 2026-10-22T11:00:00.000Z Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance https://www.biopharmawatch.com/news/ACON/aclarion-nociscan-validation-lumbar-discs BiopharmaWatch en 2026-10-22T11:00:00.000Z Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-aurora-phase-3-trial-denifanstat-acne BiopharmaWatch en 2026-10-22T11:00:00.000Z Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-foundation-medicine-collaboration BiopharmaWatch en 2026-10-22T11:00:00.000Z BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/OCGN/ocugen-business-update-q3-2026-results BiopharmaWatch en 2026-10-22T11:00:00.000Z Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 https://www.biopharmawatch.com/news/GENB/generate-biomedicines-investor-conferences-november-2026 BiopharmaWatch en 2026-10-22T11:00:00.000Z Generate Biomedicines to Participate in November Investor Conferences https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-jamie-preston-appointment BiopharmaWatch en 2026-10-22T10:53:00.000Z Elanco Animal Health Appoints Jamie Preston as Chief People Officer https://www.biopharmawatch.com/news/DGX/quest-diagnostics-q3-2026-financial-results BiopharmaWatch en 2026-10-22T10:46:00.000Z Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 https://www.biopharmawatch.com/news/TFX/teleflex-fda-breakthrough-device-freesolve-scaffold BiopharmaWatch en 2026-10-22T10:45:00.000Z Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold https://www.biopharmawatch.com/news/BNTX/biontech-phase-3-trial-pumitamig-gilead-trop2-adc BiopharmaWatch en 2026-10-22T10:45:00.000Z BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer https://www.biopharmawatch.com/news/TFX/teleflex-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-22T10:30:00.000Z Teleflex Announces Third Quarter 2026 Earnings Conference Call Information https://www.biopharmawatch.com/news/AVAH/aveanna-q3-2026-earnings-release-conference-call BiopharmaWatch en 2026-10-22T10:30:00.000Z Aveanna Announces Third Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/ONC/beone-medicines-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-22T10:01:00.000Z BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5 https://www.biopharmawatch.com/news/SMMT/ivonescimab-data-esmo-2026 BiopharmaWatch en 2026-10-22T10:00:00.000Z Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026 https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-fda-phase-3-trial-zervimesine-dlb BiopharmaWatch en 2026-10-22T10:00:00.000Z Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies https://www.biopharmawatch.com/news/BDSX/biodesix-q3-2026-financial-results-release BiopharmaWatch en 2026-10-22T10:00:00.000Z Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/OCS/oculis-privosegtor-phase-2-acuity-results BiopharmaWatch en 2026-10-22T06:00:00.000Z Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis https://www.biopharmawatch.com/news/MOLN/molecular-partners-nominates-mp0730-radiotherapeutics BiopharmaWatch en 2026-10-22T05:00:30.000Z Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70 https://www.biopharmawatch.com/news/ARGX/argenx-q3-2026-financial-results-update BiopharmaWatch en 2026-10-22T05:00:00.000Z argenx Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PHAR/pharming-group-q3-2026-revenue-report BiopharmaWatch en 2026-10-22T05:00:00.000Z Pharming Group announces third quarter 2026 revenues above market expectations https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-250-million-offering BiopharmaWatch en 2026-10-22T02:53:00.000Z Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-reverse-stock-split-nasdaq-compliance BiopharmaWatch en 2026-10-22T02:00:00.000Z Healthcare Triangle, Inc. Announces 1-for-20 Reverse Stock Split as Part of Nasdaq Compliance Plan https://www.biopharmawatch.com/news/SUPN/supernus-orphan-drug-exclusivity-onapgo BiopharmaWatch en 2026-10-21T23:45:00.000Z Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) https://www.biopharmawatch.com/news/TKNO/teknova-q3-2026-financial-results-report BiopharmaWatch en 2026-10-21T22:30:00.000Z Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-multifiltratepro-launch BiopharmaWatch en 2026-10-21T22:10:00.000Z Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™ https://www.biopharmawatch.com/news/QGEN/qiagen-preliminary-q3-2026-results BiopharmaWatch en 2026-10-21T21:44:00.000Z QIAGEN reports preliminary Q3 2026 results https://www.biopharmawatch.com/news/QGEN/qiagen-eqt-private-equity-takeover-offer BiopharmaWatch en 2026-10-21T21:43:00.000Z QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q3-2026-results-announcement BiopharmaWatch en 2026-10-21T21:40:00.000Z Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 https://www.biopharmawatch.com/news/EXOZ/exozymes-ceo-fireside-chat-commercialization-strategy BiopharmaWatch en 2026-10-21T20:30:00.000Z eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-q3-2026-results-call BiopharmaWatch en 2026-10-21T20:30:00.000Z Guardian Pharmacy Services, Inc. to Report Third Quarter 2026 Financial Results and Host Conference Call https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-public-offering-common-stock BiopharmaWatch en 2026-10-21T20:22:00.000Z Arcus Biosciences Announces Commencement of Public Offering of Common Stock https://www.biopharmawatch.com/news/MOH/molina-healthcare-reports-q3-2026-results BiopharmaWatch en 2026-10-21T20:15:00.000Z Molina Healthcare Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARDT/ardent-health-appoints-gaurav-khanna-cdio BiopharmaWatch en 2026-10-21T20:15:00.000Z Ardent Health Appoints Gaurav Khanna as Chief Digital & Information Officer https://www.biopharmawatch.com/news/MEDP/medpace-holdings-q3-2026-results BiopharmaWatch en 2026-10-21T20:15:00.000Z Medpace Holdings, Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/EHTH/ehealth-q3-2026-earnings-call-details BiopharmaWatch en 2026-10-21T20:15:00.000Z eHealth, Inc. to Hold Third Quarter 2026 Earnings Call on November 4 at 5:00 p.m. Eastern Time https://www.biopharmawatch.com/news/HELP/helus-pharma-clinical-program-advancements BiopharmaWatch en 2026-10-21T20:10:27.000Z Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 https://www.biopharmawatch.com/news/ULS/ul-solutions-expands-epr-capabilities BiopharmaWatch en 2026-10-21T20:10:00.000Z UL Solutions Expands Capabilities to Help Companies Navigate Growing Packaging and Sustainability Regulations https://www.biopharmawatch.com/news/BTMD/biote-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-21T20:05:00.000Z Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q3-2026-results-announcement BiopharmaWatch en 2026-10-21T20:05:00.000Z Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/VIR/vir-biotechnology-conference-call-q3-2026 BiopharmaWatch en 2026-10-21T20:05:00.000Z Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-fda-orphan-drug-onvansertib-cmml BiopharmaWatch en 2026-10-21T20:05:00.000Z Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia https://www.biopharmawatch.com/news/SCYX/scynexis-scy-247-idweek-presentation BiopharmaWatch en 2026-10-21T20:05:00.000Z SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek https://www.biopharmawatch.com/news/SERA/sera-prognostics-q3-2026-financial-results-webcast BiopharmaWatch en 2026-10-21T20:05:00.000Z SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-10-21T20:05:00.000Z Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 https://www.biopharmawatch.com/news/ARAY/accuray-report-first-quarter-fiscal-2027-results BiopharmaWatch en 2026-10-21T20:05:00.000Z Accuray to Report First Quarter Fiscal 2027 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/NUVB/nuvation-bio-q3-2026-results-update BiopharmaWatch en 2026-10-21T20:05:00.000Z Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q3-2026-results-webcast BiopharmaWatch en 2026-10-21T20:05:00.000Z Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 https://www.biopharmawatch.com/news/SEER/seer-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-21T20:05:00.000Z Seer to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/OM/outset-medical-q3-2026-results-conference-call BiopharmaWatch en 2026-10-21T20:05:00.000Z Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-10-21T20:05:00.000Z Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/SGHT/sight-sciences-q3-2026-financial-results BiopharmaWatch en 2026-10-21T20:05:00.000Z Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/GRAL/grail-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-21T20:02:00.000Z GRAIL to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GNTA/genenta-science-nasdaq-minimum-bid-price-deficiency BiopharmaWatch en 2026-10-21T20:01:00.000Z Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification https://www.biopharmawatch.com/news/STAA/staar-surgical-q3-2026-earnings-call BiopharmaWatch en 2026-10-21T20:01:00.000Z STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026 https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-virtual-fireside-chat BiopharmaWatch en 2026-10-21T20:01:00.000Z U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-21T20:01:00.000Z Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BCRX/biocryst-reports-q3-2026-results-november-4 BiopharmaWatch en 2026-10-21T20:01:00.000Z BioCryst to Report Third Quarter 2026 Financial Results on November 4 https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-q3-results-november-2026 BiopharmaWatch en 2026-10-21T20:00:00.000Z Cytokinetics to Announce Third Quarter Results on November 4, 2026 https://www.biopharmawatch.com/news/ARQT/arcutis-report-q3-2026-results-conference-call BiopharmaWatch en 2026-10-21T20:00:00.000Z Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026 https://www.biopharmawatch.com/news/OPK/opko-health-agreement-sell-bioreference-health-assets BiopharmaWatch en 2026-10-21T18:35:00.000Z Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp https://www.biopharmawatch.com/news/SVRA/savara-molgramostim-aPAP-data-chest-2026 BiopharmaWatch en 2026-10-21T17:10:00.000Z Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment